SUVEN CTP3S1502HT6 (Alzheimer's Disease with Agitation)
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type.
Inclusion Criteria:
- 50 years to 9o years
- Alzheimer’s Dementia (full criteria in link below)
What to Expect
- Study medication will be administered orally once-daily from Day 1 through Day 85. Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study
For more information click the link below or contact Tiffany Hoefler at thoefler@dentinstitute.com or 716-961-9219
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.